 In the United States, allopregnanolone is available only through a restricted program called the Zulresso REMS Program that requires the drug be administered by a health care provider in a certified health care facility.The REMS requires that patients be enrolled in the program prior to administration of the drug.It is given continuously by intravenous infusion over a period of 60 hours (2.5 days).